Detalles de la búsqueda
1.
A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.
Pediatr Blood Cancer
; 65(2)2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29090526
2.
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Br J Clin Pharmacol
; 80(5): 1001-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25900065
3.
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Lancet Oncol
; 15(3): 343-52, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24521993
4.
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
Int J Clin Pharmacol Ther
; 51(7): 537-48, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23547849
5.
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
CPT Pharmacometrics Syst Pharmacol
; 12(11): 1804-1818, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964753
6.
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Sci Transl Med
; 15(695): eabp9229, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163618
7.
Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Int J Clin Pharmacol Ther
; 50(8): 566-72, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22735461
8.
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B-Cell Hematological Malignancies.
Clin Pharmacol Ther
; 110(5): 1261-1272, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34041738
9.
Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies.
Clin Pharmacol Drug Dev
; 9(5): 651-658, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32311241
10.
Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
Clin Pharmacol Drug Dev
; 8(6): 837-843, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570831
11.
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Cancer Chemother Pharmacol
; 82(3): 395-406, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29915982
12.
Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
J Clin Pharmacol
; 58(8): 1067-1073, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29645280
13.
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
Mol Cancer Ther
; 17(7): 1464-1474, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29654069
14.
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
Cancer Chemother Pharmacol
; 79(6): 1239-1247, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28497320
15.
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Adv Ther
; 34(10): 2210-2231, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28983819
16.
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Lancet Haematol
; 3(3): e128-38, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26947201
17.
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
J Clin Oncol
; 32(17): 1782-91, 2014 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24821885
18.
Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
J Clin Pharmacol
; 53(2): 192-201, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23436264
19.
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer.
J Clin Pharmacol
; 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23504807
20.
Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
J Clin Pharmacol
; 52(4): 499-510, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21566199